Surface modified PLGA nanoparticles for brain targeting of Bacoside-A

Jose, Sajan; Sowmya, S; Cinu, T.A.; Aleykutty, NA; Thomas, Sabu; Souto, Eliana B.

doi:10.1016/j.ejps.2014.06.024

Cited by 125 publications

(62 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that spherical particles moving through a vessel do not deviate from its streamline motion unless experiencing an external force; however, in the case of aspheric particles, segregation can occur. 29 Mean particle sizes for formulations NPG1, NPG2, and NPG3 were 176.6±11.6 nm, 176.5±2.9 nm, and 182.9±2.5 nm, respectively. Span values of Gat-loaded PLGA NPs ranged between 0.7 and 1.07, with PI ,0.38, thereby reflecting a slight polydispersion in particle sizes, which indicates that the method employed for the preparation of NPs results in monodisperse distributions.…”

Section: Resultsmentioning

confidence: 99%

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Marcianes¹,

Negro²,

Garcı́a-Garcı́a³

et al. 2017

IJN

View full text Add to dashboard Cite

A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic- co -glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood–brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (−20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Marcianes¹,

Negro²,

Garcı́a-Garcı́a³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…The overall surface charge of cancer cells is normally negative [53] and positively charged nanoparticles strongly bind to the negatively charged cell membrane. Furthermore, positive nanoparticles have a much greater cytotoxicity compared to neutral nanoparticles due to being more efficient at penetrating and crossing the cell membrane of the cancer cell through endocytosis [55][56][57]. There was no correlation between zeta potential and the choice of PLGA, PVA loading, sonication time or PVA molecular weight (Table 2).…”

Section: Plga Nanoparticlesmentioning

confidence: 81%

“…The minimum zeta potential required for stability is ±30 mV and all of the nanoparticles were positively charged with a zeta potential range of +35.2 to +57.5mV (Table 2). Furthermore, zeta potential is an important feature in relation to the interaction of nanoparticles with cell membranes which is influenced by the surface charge of the nanoparticles [55]. The overall surface charge of cancer cells is normally negative [53] and positively charged nanoparticles strongly bind to the negatively charged cell membrane.…”

Section: Plga Nanoparticlesmentioning

confidence: 99%

Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer

Najlah

Ahmed

Iqbal

et al. 2017

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer in both men and women. A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. However, DSF is rapidly (4 minutes) metabolised in the bloodstream and it is this issue which is limiting its anticancer application in the clinic. We have recently demonstrated that a low dose of DSF-loaded PLGA nanoparticles supplemented with oral Cu inhibited tumour growth and reduced metastasis in a xenograft mouse lung cancer model. Here we demonstrate the influence of PLGA polymer, stabilizer loading and molecular weight as well as sonication time on the characteristics, including DSF release and the cytotoxicity of 10% w/w DSF-loaded PLGA nanoparticles. The paper demonstrates that the choice of PLGA as no significant influence on the characteristics of the nanoparticles apart from their DSF release, which is due to the differing degradation rates of the polymers. However, increasing the loading and molecular weight of the stabilizer as well as the sonication time reduced the size of the nanoparticles, reduced their ability to protect the DSF from reacting with Cu and degrading in serum, while increasing their DSF release rate and cytotoxicity. Additionally, increasing the sonication time resulted in the premature degradation of the PLGA, which increased the permeability of the nanoparticles further decreasing their ability to protect DSF from reacting with Cu and degrading in serum, while increasing their DSF release rate and cytotoxicity.

show abstract

“…The images confirm the homogenous nature of particles with a uniform and aggregation-free distribution. 41 There are different emulsion stabilizers available such as PVA, carbopol and polaxamer. Among these, PVA is found to provide homogenous particles with uniform size distribution.…”

Section: Discussionmentioning

confidence: 99%

Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles

Jahan¹,

Haddadi²

2015

IJN

View full text Add to dashboard Cite

The purpose of this study was to assess the effect of various formulation parameters on anti-CD205 antibody decorated poly( d , l -lactide co-glycolide) (PLGA) nanoparticles (NPs) in terms of their ability to target dendritic cells (DCs). In brief, emulsification solvent evaporation technique was adapted to design NP formulations using two different viscosity grades (low and high) of both ester and carboxylic acid terminated PLGA. Incorporation of ligand was achieved following physical adsorption or chemical conjugation processes. The physicochemical characterizations of formulations were executed to assess the effects of different solvents (chloroform and ethyl acetate), stabilizer percentage, polymer types, polymer viscosities, ligand-NP bonding types, cross-linkers, and cryoprotectants (sucrose and trehalose). Modification of any of these parameters shows significant improvement of physicochemical properties of NPs. Ethyl acetate was the solvent of choice for the formulations to ensure better emulsion formation. Infrared spectroscopy confirmed the presence of anti-CD205 antibody in the NP formulation. Finally, cytotoxicity assay confirmed the safety profile of the NPs for DCs. Thus, ligand modified structurally concealed PLGA NPs is a promising delivery tool for targeting DCs in vivo.

show abstract

Surface modified PLGA nanoparticles for brain targeting of Bacoside-A

Cited by 125 publications

References 39 publications

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer

Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles

Contact Info

Product

Resources

About